✦ LIBER ✦

328 Comparison of 48 or 72 weeks of treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C infected with HCV genotype 1

✍ Scribed by Thomas Berg; M. Von Wagner; H. Hinrichsen; T. Heintges; P. Buggisch; T. Goeser; J. Rasenack; G.R. Pape; W.E. Schmidt; B. Kallinowski; H. Klinker; U. Spengler; B. Klapperich; M. Popescu; S. Zeuzem

Book ID: 119530237
Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 122 KB
Volume: 38
Category: Article
ISSN: 0270-9139
DOI: 10.1016/s0270-9139(03)80371-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

8 24 Week treatment regimen with peginte

8 24 Week treatment regimen with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 ‘super-responders’

✍ P. Ferenci; U. Bergholz; H. Laferl; T.M. Scherzer; A. Maieron; M. Gschwantler; H 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 159 KB

522 Combination therapy with peginterfer

522 Combination therapy with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C and genotype 1 infection: Individual estimated probability of sustained virological response (SVR)

✍ O. Weiland; M.W. Fried; S.J. Hadziyannis; G.R. Foster; D. Messinger; K. Freivoge 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 62 KB

187 Efficacy and safety of 22 weeks of m

187 Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2A (40KD) (PEGASYS™) alone versus peginterferon alfa-2A (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of peginterferon alfa-2A (40KD) plus ribavirin: an open, multicenter, randomized trial

✍ Jean-Pierre Bronowicki; Denis Ouzan; Arnaud Tzanck; Tarik Asselah; Herve Desmora 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB

1207 High-dose peginterferon alfa-2A (40

1207 High-dose peginterferon alfa-2A (40KD) (PEGASYS) and ribavirin (COPEGUS) in patients infected with hepatitis C virus (HCV) genotype 1 who failed to respond to interferon alfa and ribavirin

✍ DIAGO, M; ROMEROGOMEZ, M; DEVALME, H; CRESPO, J; VALDECILLA, H; OLVEIRA, A; LAPA 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 328 KB

Treatment of patients with chronic hepat

Treatment of patients with chronic hepatitis C (CHC) with peginterferon alfa-2a (40KD) (Pegasys) alone or in combination with ribavirin (copegus) results in long-lasting sustained virological response

✍ M. Swain; M.-Y. Lai; M.L. Shiffman; W.G. Cooksley; A. Abergel; M. Diago; M. Brun 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 159 KB

Treatment of insulin resistance with met

Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin

✍ Manuel Romero-Gómez; Moisés Diago; Raúl J. Andrade; José L. Calleja; Javier Salm 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB 👁 1 views

Insulin resistance affects sustained virological response (SVR) in chronic hepatitis C. To know whether adding metformin to standard antiviral treatment improves SVR, we conducted a prospective, multicentered, randomized, double-blinded, placebo-controlled trial in 19 Spanish hospitals, including 12